<SEC-DOCUMENT>0000000000-21-006847.txt : 20210819
<SEC-HEADER>0000000000-21-006847.hdr.sgml : 20210819
<ACCEPTANCE-DATETIME>20210602163005
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-21-006847
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210602

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Caribou Biosciences, Inc.
		CENTRAL INDEX KEY:			0001619856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				453728228
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		UPLOAD

	BUSINESS ADDRESS:	
		STREET 1:		2929 7TH STREET, SUITE 105
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		510-982-6030

	MAIL ADDRESS:	
		STREET 1:		2929 7TH STREET, SUITE 105
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]#;VQO<E-P86-E+T1E=FEC94=R
M87DO4W5B='EP92]);6%G92](96EG:'0@,C0W+T9I;'1E<B]&;&%T941E8V]D
M92]4>7!E+UA/8FIE8W0O5VED=&@@,30R."],96YG=&@@,S8U+T)I='-097)#
M;VUP;VYE;G0@.#X^<W1R96%M"GB<[<&!     ,,@?^K=X 15 0
M
M
M
M
M
M
M
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M"U83J5T@@&P1%G"3H7!4FZX<NV,R$6PM:#;"!>>"GG!Q%%,ZAPK16+#E0+[
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MK:3?LM9=:]I%7O<^\N1EVL52)E3-B5RI732RP&YZQ7L;E9L\(;>$JFY"4DQ
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M[DJ(3BP \P1YT[%F@K@_ABI=CEE6:YUI+I*V?YA>X&ASX6TA(B(B(B(B\M>
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M1$1$KB?C-C1+]9I!-8GU^)I9PNOK:]9018]8[/]M"D8T[_[^OMJ3/#T]I?Y
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M2"6M9RS,,2T@#VF6G&@7I$\=I@Y95F)U(HP0&H*#LJ6&_5PZ[6(I\D54>'^
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MB4$1G:UNP&BOQWH[?RHR <X,'-MA]:EQQ97R4T:=NSYPPO$L9]R)T^:<%NE
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M;61&@5#\1:E*9+TI@0;D%%%^NN=% HF+<!C[RY7%65L+WNKX$3/.$RB5"<^
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MGFT;P7^/QYZ)IA_C\>HR'GN6J:,^F/Z), ^MSW;\D6"6B39M0(D- (,27I1
M85;R;$O!T0 NGHJ$ Q0!ET!L8!OPA5<H8@7BP)P)D')7&J)BN6FAJ&)K4>^%
MR+ Z(BQ_Y$FCFX%:0T$2,"Q%=BI*VQ'&"9)84Y!E,@LWLDS$4^9"J\7$?B=4
ME[0HE7&12]CKC%S?M<$>=NCGX7FPETDR9=,/#%O9W/ (*%P3V),!G&E2['M[
M_+F=*%YJ<PJMNVHT6'=2:G"!P7I'OD\9]=IS%K4-\&>[?$_1J9IU*FMM#\=>
M@:"*;Q?)777QLRR7;BIN>_,[AP(7!&D,!;UL# 6O&Q S49VRQL["< V EX3G
M .5BMD4097O :3VZX)CEZ6J<DIUC%(X$L941>]71G*K#)=<YP:76\%#1TO*<
M%[!$%T?.F*Z] )4<7":#,2H!>2["D@/N,I[?%G^IJ0FUK&:,Q2DV5'V<>CI8
M$=?A15'F:&#J/D7HE)II5'*"EAS/>X94T:*;)-\OX[Q9)V(9RZVL;Q1\W  [
M1N(R/_"DEGH9;X<'#1VJ;^4497-\4Q\"\QKX!Q)  $@95LA4L=_GA SBB:>
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MU]DHX&.M_P%R>B(:84F<.I"UX6[=A(2[QPOV0VG4$W%/HG,J0'Z@:*Z-SC*
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M<-E!! -CAS^0R+H"$6-D+)X$83$Q5C^'L)@96YPA+!;&=BN@XO8,!A#X_Q\
M,BH,M@IE;F1S=')E86T*96YD;V)J"B5I5&5X="TU+C0N-0IS=&%R='AR968*
,,S4R-#4*)25%3T8*

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo





                            June 2, 2021

       Rachel Haurwitz, Ph.D.
       President and Chief Executive Officer
       Caribou Biosciences, Inc.
       2929 7th Street, Suite 105
       Berkeley, California 94710

                                                        Re: Caribou
Biosciences, Inc.
                                                            Draft Registration
Statement on Form S-1
                                                            Submitted May 7,
2021
                                                            CIK No. 0001619856

       Dear Dr. Haurwitz:

              We have reviewed your draft registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Draft Registration Statement on Form S-1

       Prospectus Summary
       Overview, page 1

   1.                                                   Your statements that
your allogeneic CAR-T cell therapies have "best-in-class" potential
                                                        imply the likelihood of
regulatory approval and comparisons to other products and
                                                        product candidates. The
statements are speculative in light of their regulatory status.
                                                        Please remove the
"best-in-class" references.
   2.                                                   Please make the
following changes to your pipeline table:
                                                            Include all
clinical stages that must be completed before commercialization (i.e., add
                                                            columns for Phases
2 and 3).
                                                            We note the table
entitled "Programs under AbbVie collaboration" with
 Rachel Haurwitz, Ph.D.
FirstName  LastNameRachel  Haurwitz, Ph.D.
Caribou Biosciences, Inc.
Comapany
June 2, 2021NameCaribou Biosciences, Inc.
June 2,
Page 2 2021 Page 2
FirstName LastName
              "undisclosed" targets that are only discussed briefly in your
description of your
              collaboration and license agreement with AbbVie. To the extent
these are material
              programs, disclose the targets and provide descriptions of these
programs. Otherwise,
              please remove them from the table or explain the basis for your
belief that they are
              material and should be included in your pipeline table.
                Please explain what is involved in "lead optimization" and why
you believe this is a
              separate and distinct development phase, as opposed to part of
the discovery
              phases. While we will consider your response, we do not currently
believe that
              the lead optimization is distinct from the discovery phase and
should thus be depicted
              under the discovery column. A textual discussion of the program
is likely a more
              appropriate place to make distinctions regarding different
segments within a
              particular phase.
3.       We note your disclosure here and throughout the filing that you are
focused on advancing
         treatments for "clinically validated targets." Please balance these
statements throughout
         your registration statement with the disclosure on page 22 that no
products that use novel
         genome-editing technologies have advanced into clinical trials or
received marketing
         approval in the United States.
4.       You note on page 2 and throughout your filing that the February 2021
collaboration
         with AbbVie is " is an external validation of our chRDNA
genome-editing technology."
         Please revise this statement and similar statements on pages 98 and
116 to remove the
         "external validation" language, as efficacy determinations are the
exclusive purview of the
         FDA or other regulators.
5.       Please balance your disclosure on page 2 and throughout your filing
that "CB-010 is
         currently being evaluated in a phase 1 clinical trial in patients with
relapsed or refractory
         B cell non-Hodgkin lymphoma" with the fact that you have not yet
enrolled patients in
         this trial. We note your disclosure to this effect on page 26.
Risk Factors
Our rights to develop and commercialize our product candidates are subject...,
page 57

6.       Please provide additional risk factor disclosure about the dispute
with Intellia
         Therapeutics. Specifically, disclose whether your inability to reach a
"final resolution"
         with Intellia would hinder your ongoing Phase 1 trial of CB-010 and
whether you would
         be able to continue clinical development of CB-010 if this dispute is
not resolved.
Industry and Market Data, page 88

7.       We note your statements regarding market data used in the prospectus,
including that the
         sources of the information do not guarantee the accuracy or
completeness of the
         information and that investors are cautioned "not to give undue
weight" to estimates.
         Please revise these statements to eliminate any implication that
investors are not entitled
         to rely on the information included in your registration statement.
 Rachel Haurwitz, Ph.D.
FirstName  LastNameRachel  Haurwitz, Ph.D.
Caribou Biosciences, Inc.
Comapany
June 2, 2021NameCaribou Biosciences, Inc.
June 2,
Page 3 2021 Page 3
FirstName LastName
Results of Operations
Licensing and Collaboration Revenue, page 104

8.       Please describe and quantify for us revenue by license and
collaboration agreement for
         each period presented that includes reference to related information
in Note 4. In addition,
         clarify whether the "Private Company" is a related party, as
referenced on page F-8, or an
         unaffiliated company, as referenced on page F-21. Revise your
disclosure accordingly.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Critical Accounting Policies and Significant Judgments and Estimates
Stock-Based Compensation Expense, page 112

9.       Once you have an estimated offering price range, please explain to us
the reasons for any
         differences between recent valuations of your common stock leading up
to the planned
         offering and the midpoint of your estimated offering price range. This
information will
         facilitate our review of your accounting for stock compensation.
Please discuss with the
         Staff how to submit your response.
Business
Strategic Agreements, page 143

10.      Please revise the descriptions of your strategic agreements as
appropriate to revise any
         references to "low-double-digit" and "mid-double-digit" royalties to a
royalty range within
         ten percentage points (for example, between twenty and thirty percent)
and to disclose
         the expected expiry of the last-to-expire patent licensed under the
agreements.
11.      With respect to the Collaboration and License Agreement with AbbVie,
please disclose
         the fee that AbbVie must pay to expand from two Program Slots and the
maximum
         aggregate commercial milestones you may receive under the agreement.
12.      With respect to your Exclusive License Agreement with MSKCC, please
revise your
         disclosure to clarify whether the IPO would trigger a success payment.
13.      Please expand your discussion of the ProMab Agreement to disclose the
upfront payment,
         royalty term, and termination provisions.
14.      With respect to the Pioneer Agreement, please disclose the "certain
events" that permit
         either party to terminate the agreement.
Intellectual Property, page 147

15.      Please expand your intellectual property discussion to disclose the
number and type of
         patents that cover each of your product candidates and programs,
whether they are owned
         or licensed, the related jurisdiction, and the expiration year.
 Rachel Haurwitz, Ph.D.
FirstName  LastNameRachel  Haurwitz, Ph.D.
Caribou Biosciences, Inc.
Comapany
June 2, 2021NameCaribou Biosciences, Inc.
June 2,
Page 4 2021 Page 4
FirstName LastName
Legal Proceedings
Intellia Arbitration, page 167

16.      Please disclose, if known, a general timeframe for when you expect to
negotiate economic
         terms based on the revised scope of the leaseback and whether you
believe that agreeing
         to these terms will resolve the conflict underlying the Intellia
Arbitration. If not, please
         expand your disclosure to discuss how the interim award determining
that the two patent
         families are included in the Intellia License Agreement impacts any
licenses or
         sublicenses that you have granted, if at all.
Licensing Agreement Transaction, page 193

17.      You disclose that you have a license agreement with a "private
company" controlled by
         Anterra that provides for milestone payments and royalty payments for
future sales of
         licensed products. Please disclose the material terms of the license
agreement, including
         the milestone payments and the royalty range, and file the agreement
as an exhibit or tell
         us why you believe such filing is not required. Refer to Item
601(b)(10) of Regulation S-
         K.
Principal Stockholders, page 197

18.      Please identify in footnotes to the table all natural persons who have
voting and/or
         investment power over the shares held by F-Prime Capital Partners.
Financial Statements
Note 2. Summary of Significant Accounting Policies
Revenues, page F-9

19.      Please expand your disclosures to describe the nature of your
performance
         obligation associated with maintenance fees and when you satisfy your
performance
         obligation. In this regard, while you disclose herein that you
recognize revenues
         associated with annual maintenance fees on a point in time basis on
each anniversary date,
         you also disclose on page F-23 that your deferred revenue primarily
results from customer
         payments received upfront for maintenance fees because these
performance obligations
         are satisfied over time. Please address this apparent discrepancy.
Refer to your disclosure
         on page 111 as well.
General

20.      Please supplementally provide us with copies of all written
communications, as defined in
         Rule 405 under the Securities Act, that you, or anyone authorized to
do so on your behalf,
         present to potential investors in reliance on Section 5(d) of the
Securities Act, whether or
         not they retain copies of the communications.
 Rachel Haurwitz, Ph.D.
Caribou Biosciences, Inc.
June 2, 2021
Page 5



       You may contact Franklin Wyman at 202-551-3660 or Jeanne Baker at
202-551-3691 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Dillon Hagius at 202-551-7967 or Irene Paik at 202-551-6553 with any
other questions.



                                                          Sincerely,
FirstName LastNameRachel Haurwitz, Ph.D.
                                                          Division of
Corporation Finance
Comapany NameCaribou Biosciences, Inc.
                                                          Office of Life
Sciences
June 2, 2021 Page 5
cc:       Ashok Mukhey
FirstName LastName
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
